Scholarlink

<p>Advances in high-throughput sequencing and decreasing costs have made cell-free DNA sequencing a promising approach for cancer detection. Sequencing assays require high read depth to detect low-frequency somatic mutations, so cell-free DNA panels must support deep sequencing while still assaying broadly enough to detect as many malignancies as possible. We developed OPTIC (Oncogene Panel Tester for Identifying Cancers), a pipeline employing a set cover algorithm, to identify the minimal set of genomic targets capturing the maximal proportion of tumours. Using three cohorts totalling 2,940 colorectal cancer samples, OPTIC was utilized to design a targeted sequencing panel spanning just 10,975 bases across <i>APC, TP53, KRAS, BRAF, NRAS, PIK3CA, CTNNB1, RNF43</i>, and <i>ACVR2A</i>. Collectively, these loci contain pathogenic mutations in 96.3% of cases. Our pipeline enables compact panel design without compromising sample coverage. This enables higher throughput, greater sequencing depth, and lower costs per-sample in early colorectal cancer detection from cell-free DNA.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A set cover algorithm identifies minimal circulating tumour DNA sequencing targets for colorectal cancer detection

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月20日

查看全文
  • Kit Moloney-Geany,
  • Michael A. Black,
  • Robert C. Day,
  • Parry Guilford,
  • Michael J. Dunnet

摘要

Advances in high-throughput sequencing and decreasing costs have made cell-free DNA sequencing a promising approach for cancer detection. Sequencing assays require high read depth to detect low-frequency somatic mutations, so cell-free DNA panels must support deep sequencing while still assaying broadly enough to detect as many malignancies as possible. We developed OPTIC (Oncogene Panel Tester for Identifying Cancers), a pipeline employing a set cover algorithm, to identify the minimal set of genomic targets capturing the maximal proportion of tumours. Using three cohorts totalling 2,940 colorectal cancer samples, OPTIC was utilized to design a targeted sequencing panel spanning just 10,975 bases across APC, TP53, KRAS, BRAF, NRAS, PIK3CA, CTNNB1, RNF43, and ACVR2A. Collectively, these loci contain pathogenic mutations in 96.3% of cases. Our pipeline enables compact panel design without compromising sample coverage. This enables higher throughput, greater sequencing depth, and lower costs per-sample in early colorectal cancer detection from cell-free DNA.